Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2022-02-09
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with
head and neck squamous cell cancer that has come back or spread to other places in the body
and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere
with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor
cells by blocking some of the pathways needed for cell growth. Giving pembrolizumab and
cabozantinib may improve the chances of tumor response in patients with head and neck
squamous cell cancer.